Na-Phenylbutyrate VAscular Trial

Sponsor
University of Pennsylvania
Study ID
NCT06645769
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Sodium Phenylbutyrate — DRUG
    will be compared to placebo
  • Placebo — OTHER
    will be compared to NaPB

Study Details

This study will investigate if the drug sodium phenylbutyrate (NaPB) impacts blood pressure and vascular function in healthy volunteers and in patients with diabetes.

Key Dates

First listed
Oct 17, 2024
Start date
Jun 1, 2026
Status verified
Mar 2026
Primary completion
Jan 1, 2028
Completion
Jun 1, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: NaPB administration
  • Placebo Comparator: Placebo control

Primary Outcome Measure

Systemic vascular resistance [ Time Frame: from enrollment to the end of participation at 8 weeks ]

Central Contacts

Related Studies